(Q43040452)

12 November 2017

title

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis (English)

1 reference

12 November 2017

0 references

hepatocellular carcinoma

1 reference

2

1 reference

12 November 2017

G Nkontchou

1

1 reference

12 November 2017

M Aout

3

1 reference

12 November 2017

M Lhabadie

4

1 reference

12 November 2017

Y Baazia

5

1 reference

12 November 2017

A Mahmoudi

6

1 reference

12 November 2017

D Roulot

7

1 reference

12 November 2017

N Ganne-Carrie

8

1 reference

12 November 2017

V Grando-Lemaire

9

1 reference

12 November 2017

J-C Trinchet

10

1 reference

12 November 2017

E Gordien

11

1 reference

12 November 2017

E Vicaut

12

1 reference

12 November 2017

I Baghad

13

1 reference

12 November 2017

M Beaugrand

14

1 reference

12 November 2017

publication date

1 October 2011

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

18

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

e516-22

1 reference

Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01441.X

10.1111/J.1365-2893.2011.01441.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference